Searchable abstracts of presentations at key conferences in endocrinology

ea0081p595 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Somatostatin analogue treatment for hyperinsulinemic hypoglycemia with glucokinase activating mutation (GCK), c.295T>C (p.Trp99Arg)

Boguslawska Anna , Rzepka Ewelina , Kluczyński Lukasz , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Somatostatin analogues (SSA) are used to treat different forms of hyperinsulinemic hypoglycemia (HH) in children and adults and therapeutic effect is achieved by suppressing insulin secretion from pancreatic β-cells by complex mechanisms. These treatments might be associated with several side effects, can even cause the worsening of severity of hypoglycemia. This is a report of the treatment of HH with SSA in patient with Activating Mutation (GCK), c.295T>C (p.Trp99Ar...

ea0090p435 | Pituitary and Neuroendocrinology | ECE2023

Osilodrostat as an effective and safe treatment for ectopic Cushing Syndrome- case report

Minasyan Mari , Boguslawska Anna , Rzepka Ewelina , Kluczyński Łukasz , Gilis-Januszewska Aleksandra , Hubalewska-Dydejczyk Alicja

Osilodrostat as an inhibitor of adrenal 11B-hydroxylas, is an effective medication used in the management of endogenous hypercortisolism. There are limited data regarding usage of osilodrostat in ectopic Cushing Syndrome (CS). Surgery is usually the first line treatment in ectopic CS, however the source of ectopic hormonal production often remains undiscovered for a long period of time. Meanwhile dangerous state of severe hypercortisolism needs to be managed pharmacologically ...